21:13 , Jan 5, 2018 |  BC Week In Review  |  Financial News

NexImmune raises $23M series A

NexImmune Inc. (Gaithersburg, Md.) raised $23 million on Jan. 2 in a series A round co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont Capital also participated. The immuno-oncology...
21:01 , Jan 2, 2018 |  BC Extra  |  Financial News

NexImmune raises $23M series A

NexImmune Inc. (Gaithersburg, Md.) raised $23 million in a series A round co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont Capital also participated. The immuno-oncology company expects the...
20:39 , Feb 17, 2017 |  BioCentury  |  Finance

NexImmune’s next act

Management’s and investors’ different views about what product to develop first was the catalyst for the sale of immuno-oncology play NexImmune Inc. to a new syndicate led by Sol Barer, chairman of Teva Pharmaceutical Industries...
20:32 , Feb 16, 2017 |  BC Week In Review  |  Company News

NexImmune deal

An investor group acquired immuno-oncology company NexImmune for an undisclosed amount. The group includes Sol Barer, former Celgene Corp. (NASDAQ:CELG, Summit, N.J.) chairman and CEO and current chairman of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel...
18:08 , Feb 14, 2017 |  BC Extra  |  Financial News

Barer among investors acquiring NexImmune

An investor group including former CEOs of Celgene Corp. (NASDAQ:CELG) and Medtronic plc (NYSE:MDT) has acquired immuno-oncology company NexImmune Inc. (Gaithersburg, Md.) for an undisclosed amount. The group includes Sol Barer, the former Celgene chairman and...